• GSK presented positive results for Mo-Rez in platinum-resistant ovarian cancer from the phase I BEHOLD-1 trial.
• Common side effects were gastrointestinal and hematological, consistent with the treatment class; treatment-related adverse events prompted dose interruptions or reductions.
• Five pivotal phase III trials are underway across ovarian and endometrial cancers.
• Endometrial cancer patients receiving the selected phase III dose remain under follow-up, with results expected to be presented in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.